Key result
Pharmacological or genetic inhibition of site-1 protease suppresses soluble PRR production and attenuates macrophage infiltration, thereby blunting ischemic acute kidney injury.
Why the study?
Does S1P inhibition reduce inflammation and blunt ischemic acute kidney injury?
Does S1P inhibition reduce inflammation and blunt ischemic acute kidney injury?
Answers are grounded in this paper and cite their sources.
The study identifies sPRR as a mechanistically active mediator of AKI and demonstrates that S1P inhibition blunts ischemic AKI by suppressing inflammation.
Inflammation is a determining factor in acute kidney injury (AKI) and subsequent kidney repair, yet its regulation is complicated and incompletely understood. In this issue, Feng and colleagues report that site-1 protease (S1P)-dependent cleavage of the (pro)renin receptor (PRR/ATP6AP2) generates soluble PRR (sPRR), which functions as an inflammation amplifier in ischemic AKI. Remarkably, S1P inhibition pharmacologically or genetically suppresses sPRR production and attenuates macrophage infiltration and activation, blunting AKI. The work elevates sPRR from a putative biomarker to a mechanistically active mediator of AKI. It also couples innate immune programming to local renin-angiotensin system engagement, suggesting an immuno-endocrine cross-talk and modulation in the kidney.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2026) studied this question. Pharmacological or genetic inhibition of site-1 protease suppresses soluble PRR production and attenuates macrophage infiltration, thereby blunting ischemic acute kidney injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: